Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-19EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcera…
-
EMA approval · 2026-01-09EMA Authorised: Usymro (ustekinumab) — Gedeon Richter Plc.
EMA authorised Usymro (ustekinumab) by Gedeon Richter for Crohn's disease, psoriasis, and psoriatic arthritis.
-
FDA approval · 2026-01-07FDA Approved: YESINTEK — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for YESINTEK (ustekinumab) from Biocon Biologics Inc. The action relates to the ustekinumab bios…
-
FDA approval · 2025-12-23FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for OTEZLA (apremilast) from Amgen, Inc. The approval updates the labeling for the product.
-
EMA approval · 2025-12-18EMA Authorised: Cosentyx (secukinumab) — Novartis Europharm Limited
The EMA authorised Cosentyx (secukinumab) for psoriatic arthritis, psoriasis, and ankylosing spondylitis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…
-
FDA approval · 2025-12-01FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for SELARSDI (USTEKINUMAB-AEKN), a biosimilar to ustekinumab.
-
EMA approval · 2025-12-01EMA Authorised: Benepali (etanercept) — Samsung Bioepis NL B.V.
The European Medicines Agency authorised Benepali (etanercept), a biosimilar to etanercept, for inflammatory conditions including rheumatoid…
-
EMA approval · 2025-11-21EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Usgena, a ustekinumab product from STADA, for treatment of Crohn's disease, psoriasis, psoriatic ar…
-
EMA approval · 2025-11-21EMA Authorised: Pyzchiva (ustekinumab) — Samsung Bioepis NL B.V.
EMA authorised Pyzchiva (ustekinumab) for Crohn's disease, ulcerative colitis, and psoriatic arthritis.
-
FDA approval · 2025-11-20FDA Approved: IMULDOSA — Supplemental Application (Accord BioPharma Inc.)
FDA approved a supplemental application for IMULDOSA (USTEKINUMAB-SRLF) from Accord BioPharma Inc. The action updates the regulatory status …
-
EMA approval · 2025-11-20EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
The EMA authorised Gobivaz (golimumab) for multiple inflammatory diseases. Indications include rheumatoid arthritis, juvenile idiopathic art…
-
FDA approval · 2025-11-19FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aeKn) from Teva Pharmaceuticals USA, Inc. The product is a ustekinumab bio…
-
FDA approval · 2025-11-18FDA Approved: USTEKINUMAB-TTWE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
EMA approval · 2025-11-10EMA Authorised: Flixabi (infliximab) — Samsung Bioepis NL B.V.
The EMA authorised Flixabi, a biosimilar of infliximab, for several inflammatory diseases. The indications include rheumatoid arthritis, pso…
-
FDA approval · 2025-11-03FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for Ustekinumab (Stelara) from Janssen Biotech, Inc., related to regulatory changes to its label…
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
-
EMA approval · 2025-10-17EMA Authorised: Arava (leflunomide) — Sanofi-aventis Deutschland GmbH
The European Medicines Agency authorised Arava (leflunomide) for the treatment of rheumatoid arthritis and psoriatic arthritis, with Sanofi-…
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.